MorphoSys AG has announced plans to acquire Constellation Pharmaceuticals Inc, one of the first US companies to develop drugs in the field of epigenetics. Germany-based MorphoSys will pay $1.7 billion for the company, which has two clinical-stage cancer programmes and several projects in preclinical development.
